Biden Budget Gives Drug Pricing Reform A Spotlight But No Specifics
Executive Summary
Approach leaves policy development to Congress. The President understands the need to build consensus around specific policies to achieve his goals, White House Office of Management and Budget Acting Director Shalanda Young explains.
You may also be interested in...
A Presidential Punt On Drug Pricing
White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.